Two-Day Deadline Approaches for Spectrum Pharmaceuticals Investors in Class Action Lawsuit

Attention Spectrum Pharmaceuticals Investors

The recent announcement concerning Spectrum Pharmaceuticals (SPPI) offers significant news for investors involved in the ongoing securities class action. After a brief suspension, the lead plaintiff process has been reopened by a New York federal court, allowing new investors to represent the class.

Key Details

The lead plaintiff position became available after the previous appointee was disqualified on August 4, 2025. Investors need to act quickly, as the deadline to apply is set for September 24, 2025.

Eligible investors include those who purchased Spectrum common shares on the open market during the class period, which spans from March 17, 2022, to September 22, 2022. Additionally, investors who received shares of Assertio Holdings (ASRT) through Spectrum's acquisition on July 31, 2023, may also qualify. This lawsuit has already withstood a motion to dismiss, giving involved parties an encouraging outlook.

Background of the Lawsuit

The federal class action, Christiansen v. Spectrum Pharmaceuticals, Inc., has been making headlines since late 2022. It alleges that throughout the class period, Spectrum Securities misinformed investors by claiming the efficacy of its cancer drug, poziotinib, despite internal acknowledgment of its shortcomings. When the FDA raised concerns about clinical trial outcomes, Spectrum’s stock took a nosedive, shedding over 37% of its value.

Given these circumstances, the relevance for potential lead plaintiffs is paramount. The case had previously progressed towards class certification in October 2023 but was halted due to misconduct allegations against the earlier appointed lead plaintiff. Until a new lead is appointed, the case remains stalled.

The Acquisition by Assertio Holdings

In a noteworthy turn of events, Assertio Holdings completed its acquisition of Spectrum Pharmaceuticals in July 2023. This merger marks a pivotal moment, as it connects directly to the current class action. Investors who had acquired Spectrum shares during the relevant period and later transitioned to Assertio shares could find themselves pivotal in the lead plaintiff selection process.

Call to Action

Hagens Berman, the national shareholders' rights law firm advocating for affected investors, is currently investigating these claims. The firm is extending its support to individuals who endured substantial financial losses because of the alleged misconduct. Stepping into the lead plaintiff role not only allows investors to take charge of the litigation process but also safeguards the collective interests of all class members.

Furthermore, whistleblowers holding non-public information about Spectrum are urged to consider their options within the SEC Whistleblower program, which can offer substantial financial rewards.

Reaching Out for Assistance

For investors keen on participating or seeking additional information regarding the case, Hagens Berman provides multiple avenues for engagement. Interested individuals can visit hbsslaw.com/investor-fraud/sppi or contact the firm via phone at 844-916-0895 or by email at [email protected].

These next steps are critical, and involvement now could prove decisive in the ongoing pursuit of justice and recovery for affected investors in the Spectrum Pharmaceuticals case.